Vuity vs Izervay
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Vuity | US Izervay | |
|---|---|---|
| Generic name | pilocarpine ophthalmic | avacincaptad pegol |
| Drug class | Cholinergic Muscarinic Agonist (Eye Drop) | Complement C5 Inhibitor |
| Treats | Age-related blurry near vision (presbyopia) | Geographic atrophy (advanced dry AMD) |
| Category | Eye Health | Eye Health |
| Manufacturer | AbbVie (Allergan) | Astellas Pharma |
| Year approved | 2021 | 2023 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $70M | — |
| Common side effects | Headache, Eye redness, Trouble with night vision, Eye pain | Bleeding in the eye, Increased eye pressure, Floaters, Risk of eye infection |
Frequently asked questions
Is Vuity or Izervay better?
Neither is universally "better." Vuity (pilocarpine ophthalmic) and Izervay (avacincaptad pegol) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vuity and Izervay?
Vuity is a Cholinergic Muscarinic Agonist (Eye Drop) made by AbbVie (Allergan), while Izervay is a Complement C5 Inhibitor made by Astellas Pharma. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vuity has the larger estimated TV advertising budget of the two.